Editor’s Note: The title of the story has been updated. The original title incorrectly stated that the device is implantable
On Monday, Nexalin Technology, Inc. (NASDAQ:NXL) announced the publication of a study in the Journal of Alzheimer’s Disease.
The study builds on recent findings from Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease (AD).
The new research involved 46 randomly assigned patients receiving either real DIFS or sham treatment for 30 one-hour sessions over three weeks.
Resting-state functional magnetic resonance imaging (rs-fMRI) was used to track changes in brain activity.
Key Findings of the Study Include:
The study indicated no serious side effects reported among participants.
Despite undergoing twice-daily stimulation sessions over three weeks, elderly patients tolerated the treatment well, with only minor sensations such as tingling that resolved quickly.
The company adds that Alzheimer’s disease affects over 50 million people globally, and it is projected to rise to over 113 million by 2050.
Price Action: NXL stock is down 4.37% at $2.19 during the premarket session at last check Monday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
